CLP 1001
Alternative Names: CLP; CLP1001Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Sorbent Therapeutics
- Class Heart failure therapies; Polymers
- Mechanism of Action Sodium-potassium-chloride symporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 12 Jan 2016 No recent reports on development identified - Phase-II for Heart failure in USA, Argentina, Israel (PO)
- 25 Jun 2015 No recent reports of development identified - Phase-II for Heart failure in Moldova, Armenia and Georgia (PO)
- 15 May 2014 Sorbent Therapeutics completes enrolment in its phase II trial for Heart failure in Argentina, Israel and USA (NCT01736735)